Introduction
Conclusive evidence exists that hypertension is a reversible risk factor, that is, the reduction of the elevated blood pressure by treatment reduces the risk of fatal and non-fatal cardiovascular events associated with this condition. 1 Yet, despite the availability of effective treatment strategies, in everyday practice, the blood pressure control has a worldwide low rate, due to a combination of underdiagnosis and undertreatment. This is responsible for the fact that hypertension is the first cause of death worldwide and one of the major contributors to the burden of disease. 2, 3 Socioeconomic factors, such as income, education and ethnicity, have been extensively investigated as possibly associated with the rate of treatment and control of hypertension. [4] [5] [6] [7] [8] [9] However, data on this issue mainly reflect private, or mixed publicprivate, health care systems. Despite the fact that the Italian National Health Service (NHS) provides universal coverage for health care, including drug treatment for hypertension, socioeconomic disparities in the occurrence of coronary heart disease still persist. 10 The purpose of this study was to explore whether socioeconomic factors such as income, ethnicity and household composition (that is, living or not living alone) are associated with access to and stay on antihypertensive drug treatment in an unselected urban population, using the health service database of the Italian Lombardia region. Strengths of the study are (1) the extremely large size of the database, (2) the natural setting from which the data were obtained and (3) the homogeneity of the health care system, which in Italy is entirely public.
Methods

Setting
The source population included residents of the city of Milan, the capital of the Lombardia region and the most populous city of Northern Italy. It has a population of more than 1 million inhabitants. This population is entirely covered by the NHS that has administered this programme since 1997. It utilizes an automated system of databases on the use of health services including demographic and administrative data, hospital discharge and outpatient prescription of drugs reimbursable from the NHS. Health data are recorded for the beneficiaries of the NHS (the whole resident population) and can be linked for each individual using a unique personal identification code. In addition, individual data from the tax registry of the city of Milan, which makes use of the same personal identification code, were linked with the health data.
To prevent the identification of individual data and thus protect privacy, each identification code was automatically converted to a unique and anonymous code, the inverse process being prevented by the deletion of the conversion table.
Identifying new users of antihypertensive drugs All beneficiaries of the NHS residents in the city of Milan aged 40-80 years represented the source population. According to the 2001 Italian census, this population comprised 644 536 individuals. Among them, those who received at least one antihypertensive agent from 1 January 1999 to 31 December 2002 were identified as eligible patients. The date of the first dispensation of an antihypertensive agent during this period were designed as the index date. To ensure the selection of only newly treated individuals, eligible patients at whom at least one prescription for hypertension was dispensed within the 2 years before the index date (prevalent users) were excluded. Patients who received only one antihypertensive canister during the first year after the index date (sporadic users) were also excluded. The remaining patients constituted the study cohort.
Assessing socioeconomic characteristics Socioeconomic data were obtained from the local tax registry and consisted of taxable income, nationality and household composition. We used the formula that is frequently applied in income inequality studies to calculate the individual income, which consists of dividing the household income by the square root of the number of household members. 11 When counting the number of household members, the first adult of a family was weighted as 1.0, other adults as 0.7 and children less than 18 years old as 0.5. The equivalent income (net household income divided by equivalence factor) therefore indicates the net income per month that is available for one person. The equivalent income was categorized into equal-sized quintile categories. We considered the nationality to distinguish Italian individuals from individuals who immigrated from non-western (Africa, Asia, Central or South America or East Europe) or western countries (European Community, North America or Oceania). The household composition was considered to distinguish persons who live alone from those who live with a partner or within a family context.
Evaluating discontinuation of antihypertensive therapy
The duration of all prescriptions dispensed to each member of the cohort was calculated by dividing the total amount of drug prescribed by the defined daily dose. Starting from the index date, consecutively refilled prescriptions were assigned to a unique therapeutic cycle, if an antihypertensive drug was prescribed within 90 days following the end of the latest dispensation. Treatment discontinuation was assumed otherwise and the date at which the last consecutive prescription expired was considered the discontinuation date.
Data analysis
We calculated the incidence rate of new users of antihypertensive drugs for each stratum of socioeconomic characteristics. The source population was constituted from the residents in the city of Milan excluding prevalent and sporadic users of antihypertensive drugs. Rates were standardized according to the demographic (gender and 10-year intervals of age) and socioeconomic structure of the source population (direct standardization). Findings were expressed as standardized incidence rates (SIR). The corresponding 95% confidence intervals (CIs) were calculated on the assumption that the observed number of new antihypertensive users followed a Poisson distribution. Differences in SIR were evaluated by testing their heterogeneity between strata according to Esteve et al. 12 Contrasts comparing strata-specific SIRs were also evaluated, when feasible, and their significance were tested after Bonferroni correction.
Afterwards, we calculated the effect of socioeconomic characteristics on the type of antihypertensive drug therapy refilled at the index date (combined therapy vs monotherapy), as well as on the additional use of drugs suggestive of other conditions besides hypertension, that is, heart failure (digitals glycosides), coronary heart disease (nitrates) or diabetes (antidiabetic drugs) among the cohort members at entry or during follow-up. Multivariate logistic regression models were fitted to compute odds ratios (ORs), and corresponding 95% CI, estimating the effect of socioeconomic factors on the considered outcomes after correcting for gender, age and the calendar year of the initial treatment.
Finally, we investigated the time of the first episode of treatment discontinuation occurrence among the cohort members. Each cohort member accumulated person-months at risk from the index date until the earliest between the dates of failure (discontinuation), or censoring (death, hospital admission, emigration or 1 year after index date, whichever was the earliest). Cumulative proportion of discontinuers was computed by means of the Kaplan-Meier estimator. 13 A Cox proportional hazard regression model was fitted to compute the hazard ratios (HR) and corresponding 95% CI, estimating the effect of socioeconomic factors on the risk of discontinuation. 13 Estimates were adjusted for gender, age, calendar year of treatment starting, kind of antihypertensive therapy refilled at index date and use of non-antihypertensive drugs.
For all hypotheses tested, two-tailed P-values less than 0.05 were considered as significant.
Results
We obtained data for 289 702 subjects aged 40-80 years who during 1999-2002 were treated at least once for hypertension and were recorded at the municipal register. Among these, 168 148 patients were excluded because they had already received an antihypertensive drug within 2 years before the index date. Among the remaining 121 554 subjects, 50 085 (41.2%) were excluded because they received only one antihypertensive prescription during the first year following the index date. Thus, the study cohort comprised 71 469 new users of antihypertensive medications. Table 1 shows the patient cohort separately for demographic and clinical categories. The majority of the included patients were women (55%). Mean age (s.d.) at entry was 63 years (10) . Initial treatment mainly consisted of monotherapy (82%), mostly with angiotensine converting enzyme (ACE) inhibitors (27%), diuretics (16%), b-blockers (15%) and calcium channel blockers (14%). Almost 10% of Table 3 shows the association between socioeconomic characteristics and the odds of starting with combined antihypertensive therapy, as well as of using other drugs besides hypertensive ones. The odds of starting with combined antihypertensive agents were 10% higher for patients with the lowest income compared to those with the highest income, and 18% higher for immigrants from non-western countries compared with Italians. The odds of using drugs for heart failure and diabetes showed increasing trend as income decreases and was 20 and 83% higher, respectively, in non-western immigrants compared with Italians. There were no statistical evidence that neither western immigrants nor persons living alone, respectively differed from Italians and persons living together for the odds of starting with combined antihypertensive therapy, nor for the odds of using non-antihypertensive agents.
During the first year of follow-up, the cohort accumulated 460 928 person-months at risk and generated 38 898 first discontinuing events (8.4 per 100 person-months). There was no statistical evidence that income and household composition affected the discontinuation risk (Table 4) . Immigrants from the non-western countries showed a higher rate of discontinuation treatment than Italians. Table 3 Relationship between socioeconomic characteristics and the risk of starting with combined therapy (with respect to monotherapy) and of using drugs for heart failure or diabetes (with respect of no using) 
Discussion
In this study of a large urban Italian population, we explored the role of selected socioeconomic factors on accessing and keeping antihypertensive treatment.
Our data show that, with respect to people at intermediate income, those with the highest income had 44% decreased chance of initiating antihypertensive drug therapy. It has been consistently reported that high socioeconomic profile exerts beneficial influence on cardiovascular risk factors, including hypertension. 4, [14] [15] [16] This suggests that people better off in respect to income might not much use drug therapies because of their low prevalence of hypertension. There is no doubt that the consultation of private physicians, prescription of individually paid drugs and lifestyle changes able to improve the cardiovascular risk profile and reduce blood pressure are easier where economic resources and time availability are greater, with a favourable effect on the need of blood pressure lowering drugs, which, according to guidelines, must be preceded by non-pharmacological treatment. 17 We found that, compared to subjects with intermediate income, those with the lowest income had 12% decreased chance of initiating antihypertensive drug therapy. It has been consistently reported that the prevalence of hypertension is higher among both persons at poor socioeconomic status. 14, 16 This implies that in our setting, subjects at low income do not much use drug therapies even though a high prevalence of hypertension is expected among them.
Our findings also show that among immigrants, the chance to initiate antihypertensive drug therapy was 27% less than in Italian citizens. Although it has been reported that the prevalence of hypertension is higher among immigrants, mainly those coming from African countries, 18, 19 many immigrants originate from the regions of the world where lifestyle behaviours contributing to chronic diseases, are less prevalent than those observed in the developed world. 20 This implies that the prevalence of hypertension among immigrants is expected to be heterogeneous across the immigrant groups. 21 Notwithstanding, our findings do not offer evidence that immigrants from the western and non-western countries had heterogeneous chance to initiate antihypertensive drug therapy, probably because of the high number of patients who are unaware of their hypertensive status.
Interestingly, in low income subjects and nonwestern immigrants, the lower access to antihypertensive drug treatment was associated with a greater chance to start with a combination of two drugs rather than with monotherapy, as compared to high income and Italian citizens, respectively. This may depend on the fact that in Italy several widely used combinations of two drugs, for example, those associating b-blockers, ACE inhibitors or calcium antagonists with thiazide diuretics, are cheap. It is, however, also possible that the more frequent use of combination treatment in lower socioeconomic groups reflect the fact that their rarer contact with NHS facilities mainly occurs in the presence of more severe hypertensive conditions, for which initial combination treatment is recommended. 17 This interpretation is supported by the more frequent use in these groups of drugs for heart failure and diabetes, which suggests a more common presence of comorbidities.
In agreement with other reports, [22] [23] [24] [25] [26] in our setting, more than 55% of patients had already discontinued treatment after 1 year since starting therapy. Poor socioeconomic status has been found to be related to the lack of adherence in antihypertensive drugs in previous studies. 4, 9, 27, 28 We did not find a clear relationship between income and risk of discontinuation. This suggests that the effect of income disparities in keeping with antihypertensive treatment might be mitigated from the universal coverage for drug treatment for hypertension supplied from the Italian NHS. Conversely, our findings showed that non-western immigrants had 11% risk excess of interrupting drug therapy with respect to Italian citizens.
As the considered drugs are supplied free by the Italian NHS, our finding suggests that income may be considered as a proxy for education level and, more generally, of socioeconomic status. The latter might affect the initiation of antihypertensive medicaments because of a number of mechanisms, including individual's attitudes towards health and ability to access health care. [29] [30] [31] [32] [33] [34] [35] Low rate of both initiation and keeping antihypertensive treatment observed among immigrants might be explained by the same mechanisms. In addition, a lack of understanding about their disease and its treatment might explain such evidence, since not all immigrants are able to communicate easily in the Italian language.
A main strength of our study is that patients were identified from the point of their initial antihypertensive therapy and the complete history of prescriptions was drawn out from the outpatient prescription database. This avoids differential misclassification due to over-reporting of adherence likely related to socioeconomic factors. 36 With respect to other studies based upon general practice databases, 23, 25 we included all the patients newly treated for hypertension generated from a welldefined dynamic population. This avoids the selection of patients who are assisted by physicians with higher adherence to guidelines for hypertension treatment.
There are several limitations to our analysis that merit discussion. (1) misclassification of subjects due to errors in identification and therapeutic codings and uncertain compliance of patients with their treatment certainly affected our estimates. (2) The well-known limited validity of income data might have generated misclassification bias. (3) Some patients might have bought antihypertensive drugs out from the NHS benefits and this might partially explain the lower incidence rate of antihypertensive drug use among persons at high income. (4) As prescriptions were used as a proxy for actual use of a drug, we have no direct information on real patient compliance. (5) Clinical data such as severity of hypertension, comorbidity factors and clinical complications were not available in our setting. Finally, another pitfall of the current study concerns the inability to exclude that some patients were not affected by hypertension. However, a recent Italian study has reported that hypertension represents by far the most common diagnosis (73%) for the use of antihypertensive drugs, only about 20% being used for angina pectoris, myocardial infarction and heart failure, and less than 1% for non-chronic indications, such as oedemas. 37 Moreover, in our setting, the patterns of both accessing and keeping antihypertensive drug therapy were not affected by the exclusion from our cohort of patients who concurrently used digitalis and/or nitrates. This suggests the use of antihypertensive drugs for other chronic indications such as angina and heart failure being by far minorital.
Despite the above limitations, an important conclusion of this study is that notwithstanding the universal health coverage guaranteed by the Italian NHS, social disparities still affect the access and maintenance of antihypertensive drug therapy. Persons with low or high income and immigrants are less likely to receive treatment for hypertension and moreover non-western immigrants are also likely to keep antihypertensive drug therapy. Reducing socioeconomic disparities may play a key role in lowering the rate of uncontrolled blood pressure and in reducing the rate of cardiovascular events in the general population.
